U.S. Markets closed

The Therapeutics (NASDAQ:PTCT) Share Price Is Up 289% And Shareholders Are Boasting About It

Simply Wall St

It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price goes to zero. But if you buy shares in a really great company, you can more than double your money. To wit, the PTC Therapeutics, Inc. (NASDAQ:PTCT) share price has flown 289% in the last three years. Most would be happy with that. And in the last month, the share price has gained 3.1%.

Check out our latest analysis for Therapeutics

Given that Therapeutics didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. Some companies are willing to postpone profitability to grow revenue faster, but in that case one does expect good top-line growth.

Over the last three years Therapeutics has grown its revenue at 42% annually. That's well above most pre-profit companies. Along the way, the share price gained 57% per year, a solid pop by our standards. This suggests the market has recognized the progress the business has made, at least to a significant degree. That's not to say we think the share price is too high. In fact, it might be worth keeping an eye on this one.

You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image).

NasdaqGS:PTCT Income Statement, December 3rd 2019

Balance sheet strength is crucial. It might be well worthwhile taking a look at our free report on how its financial position has changed over time.

A Different Perspective

It's nice to see that Therapeutics shareholders have received a total shareholder return of 39% over the last year. There's no doubt those recent returns are much better than the TSR loss of 2.8% per year over five years. This makes us a little wary, but the business might have turned around its fortunes. If you would like to research Therapeutics in more detail then you might want to take a look at whether insiders have been buying or selling shares in the company.

If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: insiders have been buying them).

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.